|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ALOX5 |
Gene summary for ALOX5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ALOX5 | Gene ID | 240 |
| Gene name | arachidonate 5-lipoxygenase | |
| Gene Alias | 5-LO | |
| Cytomap | 10q11.21 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P09917 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 240 | ALOX5 | CCII_1 | Human | Cervix | CC | 1.05e-05 | -4.81e-01 | 0.3249 |
| 240 | ALOX5 | Tumor | Human | Cervix | CC | 4.26e-15 | -4.77e-01 | 0.1241 |
| 240 | ALOX5 | sample1 | Human | Cervix | CC | 3.83e-05 | -4.94e-01 | 0.0959 |
| 240 | ALOX5 | sample3 | Human | Cervix | CC | 1.95e-16 | -4.78e-01 | 0.1387 |
| 240 | ALOX5 | H2 | Human | Cervix | HSIL_HPV | 1.77e-14 | -4.69e-01 | 0.0632 |
| 240 | ALOX5 | L1 | Human | Cervix | CC | 6.76e-07 | -4.51e-01 | 0.0802 |
| 240 | ALOX5 | T1 | Human | Cervix | CC | 1.19e-11 | -4.77e-01 | 0.0918 |
| 240 | ALOX5 | T3 | Human | Cervix | CC | 8.13e-12 | -4.59e-01 | 0.1389 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00464564 | Cervix | CC | icosanoid biosynthetic process | 15/2311 | 56/18723 | 2.60e-03 | 1.80e-02 | 15 |
| GO:0070206 | Cervix | CC | protein trimerization | 7/2311 | 17/18723 | 2.72e-03 | 1.85e-02 | 7 |
| GO:20003779 | Cervix | CC | regulation of reactive oxygen species metabolic process | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
| GO:19013423 | Cervix | CC | regulation of vasculature development | 60/2311 | 348/18723 | 4.48e-03 | 2.72e-02 | 60 |
| GO:00457653 | Cervix | CC | regulation of angiogenesis | 59/2311 | 342/18723 | 4.73e-03 | 2.83e-02 | 59 |
| GO:00302781 | Cervix | CC | regulation of ossification | 24/2311 | 115/18723 | 6.51e-03 | 3.61e-02 | 24 |
| GO:0030501 | Cervix | CC | positive regulation of bone mineralization | 11/2311 | 40/18723 | 7.54e-03 | 4.02e-02 | 11 |
| GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
| GO:0031214 | Cervix | CC | biomineral tissue development | 32/2311 | 169/18723 | 8.73e-03 | 4.48e-02 | 32 |
| GO:00158337 | Cervix | CC | peptide transport | 46/2311 | 264/18723 | 9.69e-03 | 4.78e-02 | 46 |
| GO:19034095 | Cervix | CC | reactive oxygen species biosynthetic process | 15/2311 | 64/18723 | 9.89e-03 | 4.85e-02 | 15 |
| GO:0030282 | Cervix | CC | bone mineralization | 24/2311 | 119/18723 | 1.00e-02 | 4.89e-02 | 24 |
| GO:0110148 | Cervix | CC | biomineralization | 32/2311 | 171/18723 | 1.04e-02 | 4.97e-02 | 32 |
| GO:004578515 | Cervix | HSIL_HPV | positive regulation of cell adhesion | 48/737 | 437/18723 | 1.37e-10 | 4.72e-08 | 48 |
| GO:000715913 | Cervix | HSIL_HPV | leukocyte cell-cell adhesion | 43/737 | 371/18723 | 2.38e-10 | 7.02e-08 | 43 |
| GO:000697915 | Cervix | HSIL_HPV | response to oxidative stress | 48/737 | 446/18723 | 2.76e-10 | 7.02e-08 | 48 |
| GO:000695912 | Cervix | HSIL_HPV | humoral immune response | 39/737 | 317/18723 | 2.88e-10 | 7.02e-08 | 39 |
| GO:002240713 | Cervix | HSIL_HPV | regulation of cell-cell adhesion | 47/737 | 448/18723 | 9.91e-10 | 2.08e-07 | 47 |
| GO:190303712 | Cervix | HSIL_HPV | regulation of leukocyte cell-cell adhesion | 38/737 | 336/18723 | 5.31e-09 | 7.61e-07 | 38 |
| GO:190303912 | Cervix | HSIL_HPV | positive regulation of leukocyte cell-cell adhesion | 31/737 | 239/18723 | 5.53e-09 | 7.61e-07 | 31 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0514514 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
| hsa0514515 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
| hsa0514522 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
| hsa0514532 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ALOX5 | SNV | Missense_Mutation | c.1112N>A | p.Arg371Gln | p.R371Q | P09917 | protein_coding | tolerated(0.21) | benign(0.03) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| ALOX5 | insertion | In_Frame_Ins | novel | c.230_231insAAACTG | p.Asn78_Asp79insTrpAsn | p.N78_D79insWN | P09917 | protein_coding | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ALOX5 | insertion | Nonsense_Mutation | novel | c.211_212insCTTCAACTTCCCAACCTTGATGAAAAGAGTGTT | p.Glu71delinsAlaSerThrSerGlnProTerTerLysGluCysTer | p.E71delinsASTSQP**KEC* | P09917 | protein_coding | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| ALOX5 | insertion | Nonsense_Mutation | novel | c.323_324insGTGA | p.Glu109Ter | p.E109* | P09917 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ALOX5 | insertion | Frame_Shift_Ins | novel | c.324_325insAAATTCTTAACACCTCCAGAACAAAGGCTCAG | p.Glu109LysfsTer15 | p.E109Kfs*15 | P09917 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| ALOX5 | SNV | Missense_Mutation | rs778612367 | c.431G>A | p.Arg144Gln | p.R144Q | P09917 | protein_coding | deleterious(0.03) | possibly_damaging(0.764) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ALOX5 | SNV | Missense_Mutation | novel | c.106C>T | p.His36Tyr | p.H36Y | P09917 | protein_coding | tolerated(0.41) | possibly_damaging(0.792) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| ALOX5 | SNV | Missense_Mutation | c.883N>A | p.Ala295Thr | p.A295T | P09917 | protein_coding | tolerated(0.42) | benign(0.187) | TCGA-EA-A5ZF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| ALOX5 | SNV | Missense_Mutation | c.685N>A | p.Glu229Lys | p.E229K | P09917 | protein_coding | deleterious(0.01) | benign(0.044) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ALOX5 | SNV | Missense_Mutation | novel | c.517N>A | p.Glu173Lys | p.E173K | P09917 | protein_coding | tolerated(0.17) | possibly_damaging(0.771) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | SKF-105809 | |||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | MESALAZINE | MESALAMINE | ||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | 6-DECYLSALICYLIC ACID | CHEMBL416038 | 24231650 | |
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | Rilopirox | RILOPIROX | ||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | SELENIUM | 14975747 | ||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | MECLOFENAMIC ACID | |||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | ZILEUTON | ZILEUTON | ||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL421 | SULFASALAZINE | |
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | ZILEUTON | ZILEUTON | ||
| 240 | ALOX5 | DRUGGABLE GENOME, ENZYME | inhibitor | 375973266 |
| Page: 1 2 3 4 5 6 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |